Browse drugs

…(c) Long-term tumor rechallenge assay without or with secretory IL-15 armoring, over 96 days, with 27 semiweekly challenges with Raji…

…es. To leverage this differential expression, we have developed PRM-CAR-T, a T cell therapy engineered to express a Chimeric Antigen Rece…

…ells, both with and without B7-H3 CAR modifications.Results Our B7-H3 CAR, PRAME-specific T cells showed a mean transduction efficien…

…ve to controls (figure 1E-F).Conclusions FUS BBBO combined with α vβ3 CAR-T cells offers a promising method for BCBM therapy. Future studies will…

…o AML platform using NOG-EXL mice, which express human IL-3 and GM-CSF to support human hematopoiesis. Mice were first engrafted with …

…roblastoma, and glioblastoma tumors, when given after a dose of 5-fluorouracil.2–4 5-FU provides myelo-depletion and releases cancer cell neoa…

…r efficacy, persistence, and safety, with the goal of advancing Dual BATs toward clinical translation.Acknowledgements The authors are af…

…tumors. Six to eight weeks later, mice were lymphodepleted with cyclophosphamide and received TCRMsln-engineered T cells and Msln peptide-pulsed…

…n. Immunogenic potential was assessed by stimulating PDTOs with IFN-γ and analyzing MHC-I and PD-L1 expression. Archival tumor sample…

…noma. Clin Cancer Res 2021;27(19):5289-5298.Kwong MLM, Yang JC. Lifileucel: FDA-approved T-cell therapy for melanoma. Oncologist 2024;29(8…

…inus of recipient mice. In a subset of recipient mice, low dose tdRT (4 Gy) was administered to recipients prior to CD45+ cell trans…

…transfer of autologous T cells from tumor fragments cultured in IL-2 has been successful in treating melanomas and select epithelial…